Porton Nominated for the 2025 Sedex Supply Chain Award

Shanghai, August 20, 2025 – Porton Pharma Solutions Ltd. (“Porton”) was honored with a nomination for the Positive Endeavors Award at the 2025 Sedex Supply Chain Award Ceremony. The recognition highlights Porton's unwavering commitment to sustainability and responsible business practices.

Sedex is a leading global platform for managing supply chains, with over 85,000 member companies worldwide. The Sedex Supply Chain Award, a flagship recognition in global supply chain management, honors companies, organizations and individuals for their contributions and innovations in advancing environmental and social responsibility.

Porton has established an ESG governance framework spanning the governance, management and execution levels, embedding sustainability into its strategy and operations. Business ethics, environmental protection, responsible supply chain practices and employee rights are integrated across processes and systems. Through regular reviews and evaluations, Porton continuously strengthens its governance mechanisms to ensure effective implementation and ongoing improvement. This approach aligns growth with sustainability while meeting rising client expectations for responsible business conduct.

As an integral part of the global pharmaceutical supply chain, Porton actively collaborates with clients to advance a sustainable future for the industry. In 2024, Porton joined the Sustainable Markets Initiative and launched green electricity procurement. In 2025, Porton's near-term science-based targets were validated by the Science Based Targets initiative (SBTi). That June, Porton announced environmental goals focused on energy, water and waste management, further aligning its practices with both its own sustainability strategy and client expectations.

Moving forward, Porton will continue to enhance its compliance management, promote sustainable development, and actively expand collaborative efforts across the industry chain to accelerate the development of a sustainable pharmaceutical ecosystem.